Ra Pharmaceuticals (RARX) reports Q4 loss per share of 47c, announces significant progress on its first XR formulation of zilucoplan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DGNX

Go back to Ra Pharmaceuticals (RARX) reports Q4 loss per share of 47c, announces significant progress on its first XR formulation of zilucoplan

Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

March 7, 2019 7:31 AM EST

Successful completion of Phase 2 trial of zilucoplan in generalized myasthenia gravis (gMG) with rapid, clinically meaningful, and statistically significant reductions in QMG and MG-ADL

Zilucoplan extended release (XR) achieves greater than one week of target drug concentrations in non-human primates following a single subcutaneous injection, supporting once weekly or less frequent dosing

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals,... More